Candel Therapeutics, Inc. (NASDAQ: CADL) announced on October 17, 2025 that it has appointed Dr. Bali Pulendran, Ph.D., a leading authority in systems immunology and vaccinology, to its Research Advisory Board (RAB). The appointment expands the company’s scientific leadership and signals a continued focus on advancing its viral immunotherapy platform.
Dr. Pulendran is the Violetta L. Horton Professor at Stanford University School of Medicine and Director of the Institute for Immunity, Transplantation and Infection. His pioneering work on dendritic cell subtypes and immune programming has been published in Nature, Science, and Cell, and he is listed among Thomson Reuters’ Highly Cited Researchers. His expertise in systems approaches to human immune responses aligns closely with Candel’s goal of eliciting robust, systemic anti‑tumor immunity from intratumoral viral delivery.
The addition of Dr. Pulendran to the RAB is expected to strengthen Candel’s development of its lead candidates, CAN‑2409 and CAN‑3110, across multiple solid tumor indications. His deep knowledge of immune response mechanisms will inform biomarker discovery, trial design, and therapeutic optimization, potentially accelerating the company’s path toward regulatory approvals and market entry.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.